Regeneron Pharmaceuticals, Inc. Plans Quarterly Dividend of $0.94 (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) declared a quarterly dividend on Thursday, July 30th. Shareholders of record on Tuesday, August 18th will be given a dividend of 0.94 per share by the biopharmaceutical company on Monday, August 31st. This represents a c) annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th.

Regeneron Pharmaceuticals has a dividend payout ratio of 9.6% indicating that its dividend is sufficiently covered by earnings. Analysts expect Regeneron Pharmaceuticals to earn $42.26 per share next year, which means the company should continue to be able to cover its $3.76 annual dividend with an expected future payout ratio of 8.9%.

Regeneron Pharmaceuticals Stock Up 6.2%

Shares of NASDAQ REGN opened at $738.34 on Friday. The company’s 50 day moving average price is $640.66 and its 200-day moving average price is $711.35. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. Regeneron Pharmaceuticals has a 52-week low of $541.00 and a 52-week high of $821.11. The company has a market capitalization of $78.06 billion, a P/E ratio of 17.99, a price-to-earnings-growth ratio of 27.78 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. During the same period in the prior year, the company posted $12.81 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 16.7% compared to the same quarter last year. Equities analysts forecast that Regeneron Pharmaceuticals will post 2.06 earnings per share for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. WPG Advisers LLC lifted its stake in shares of Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 25 shares in the last quarter. SHP Wealth Management acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $26,000. Western Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $26,000. Titan Wealth CI Ltd acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $29,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $31,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.